News

November 19, 2020 04:05 PM Eastern Standard Time ROCKVILLE, Md. & DURHAM, N.C.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms,

-Data from preclinical studies demonstrates that UNITE, as a nucleic acid platform, elicits potent immune responses in mice- November 02, 2020 08:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics,

Oct. 22, 2020 12:00 UTC Immunomic Therapeutics Announces Promotion of Dr. Tim Coleman to Senior Vice President, Operations and General Manager ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI), a privately-held

10 International Vaccine Influencers Who Exemplify Maryland’s Leading Role in Public Health Immunomic Therapeutics is listed as one of the Top 10 Maryland Vaccine Influencers in public health and Dr.

September 29, 2020 08:00 AM Eastern Daylight Time   ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that it will participate in a panel at the MD Life Sciences Bio Innovation

September 23, 2020 08:00 AM Eastern Daylight Time   ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that it will be participating in Precision Medicine’s webinar on utilizing liquid biopsy to

ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI) announced today that it will participate at the World Vaccine Congress Washington being held virtually September 28-October 1, 2020. Andrew Eisen, MD, Ph.D.,

Seoul Office Will Be Opening to Develop Immunomic Therapeutics Investigational Cell Therapy for Brain Cancer September 10, 2020 08:00 AM Eastern Daylight Time SEOUL--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held

Immunomic Therapeutics Announces Publication of Results from 3 ATTAC Studies of CMV-Specific Dendritic Cell Vaccines for the Treatment of GBM~25-35 % survival over 5 years from diagnosis in vaccinated GBM

REGISTER NOW Oncology Central powered by Future Science Group presents the panel discussion: Past, Present and Future of Immuno-oncology DATE: September 23, 2020 TIME: 10:00AM EDT/7:00AM PDT/15:00PM BST This panel

-Immunomic to invest in Replicate’s seed round; funding will enable Replicate to accelerate self-replicating RNA technology and grow operations- June 24, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md. &

-First-in-Human Phase I study is anticipated to commence in 2021- June 16, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering